A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

Inclusion Criteria:

• Participant must be ≥ 18 years old, at the time of signing the informed consent.

• Mean seated SBP on AOBPM of ≥ 140 mmHg and < 170 mmHg at Screening.

• Have a stable regimen of ≥ 3 antihypertensive medications, from differenttherapeutic classes (at least one must be a diuretic), at maximum tolerated dose inthe judgement of the Investigator, for at least 4 weeks prior to screening. Betablockers used to treat other conditions (ie, migraine, HF, coronary artery disease)should not be counted as an antihypertensive medication for the purpose ofqualifying for this study.

• Have eGFR ≥ 45 mL/min/1.73 m2 at Screening.

• Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening, determined as percentral laboratory

• Randomization Criteria: mean ambulatory SBP of ≥ 130 mmHg at randomisation.

Exclusion Criteria:

• Mean seated SBP on AOBPM ≥ 170 mmHg.

• Mean seated DBP on AOBPM ≥ 110 mmHg.

• Serum sodium level < 135 mmol/L at Screening, as per central laboratory.

• Participant has the following known secondary causes of hypertension: renal arterystenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreatedhypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.

• New York Heart Association functional HF class IV.

• Persistent atrial fibrillation.